Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$41.92

-1.05 (-2.44%)

, ARDX

Ardelyx

$3.41

-0.1 (-2.85%)

09:14
09/03/19
09/03
09:14
09/03/19
09:14

Fly Intel: Pre-market Movers

HIGHER: The Medicines Co. (MDCO), up 10% after announcing that ORION-11, its first pivotal Phase 3 clinical study of inclisiran, met all primary and secondary efficacy endpoints... Ardelyx (ARDX), up 25% after announcing the AMPLIFY study met the primary endpoint and all key secondary endpoints, including demonstrating a statistically significant reduction in serum phosphorus levels for patients treated with tenapanor and phosphate binders compared to phosphate binders alone. UP AFTER EARNINGS: Conn's (CONN), up 14%... Tufin (TUFN), up 2%. LOWER: Boeing (BA), down 3% after The Wall Street Journal reported tension between Boeing and international air-safety authorities could delay the grounded 737 Max fleet from getting back into service. Reportedly, additional weeks of delay could significantly reduce the likelihood that the 737 Max is back in the air during the Christmas holidays... Aridis (ARDS), down 27% after its AR-105 trial did not meet its primary endpoint of demonstrating superiority in clinical cure rates on Day 21 compared to placebo... ProPetro (PUMP), down 6% after disclosing that Mark Howell informed the board of directors of the company of his intent to resign from his position as the general counsel and corporate secretary of the company, effective September 29.

MDCO

The Medicines Co.

$41.92

-1.05 (-2.44%)

ARDX

Ardelyx

$3.41

-0.1 (-2.85%)

CONN

Conn's

$20.18

-0.31 (-1.51%)

TUFN

Tufin

$17.99

0.21 (1.18%)

BA

Boeing

$364.11

1.44 (0.40%)

ARDS

Aridis Pharmaceuticals

$12.40

1.02 (8.96%)

PUMP

ProPetro Holding

$10.65

-0.01 (-0.09%)

  • 03

    Sep

  • 03

    Sep

  • 03

    Sep

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

  • 19

    Sep

  • 02

    Oct

MDCO The Medicines Co.
$41.92

-1.05 (-2.44%)

09/03/19
STFL
09/03/19
NO CHANGE
Target $116
STFL
Buy
Alnylam data broadly support inclisiran as approvable drug, says Stifel
After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.
09/03/19
SBSH
09/03/19
NO CHANGE
Target $55
SBSH
Buy
The Medicines Co. price target raised to $55 from $48 at Citi
Citi analyst Joel Beatty raised his price target for The Medicines Co. to $55 from $48 following this weekend's detailed Phase 3 inclisiran data. The results suggest that inclisran is comparable on safety and efficacy to the approved PCSK9 antibody agents, Beatty tells investors in a research note. The analyst's new price target assumes a 100% probability of success for the drug. He keeps a Buy rating on The Medicines Co.
09/03/19
OPCO
09/03/19
NO CHANGE
Target $60
OPCO
Outperform
The Medicines Co. price target raised to $60 from $52 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for The Medicines Co. to $60 from $52 after the company presented details from the Phase 3 ORION-11 trial at ESC after recent topline results. The analyst believes the results "significantly de-risk" ORION-9 and -10 data to read-out sequentially in late Q3, and views The Medicines Co. as an "attractive" potential M&A target. Based on positive ORION-11 details, he also increased his Probability of Success for inclisiran to 80% from 70%. Olson reiterates an Outperform rating on the shares.
09/03/19
JPMS
09/03/19
NO CHANGE
Target $49
JPMS
Overweight
The Medicines Co. price target raised to $49 from $39 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for The Medicines Co. to $49 from $39 and keeps an Overweight rating on the shares. The analyst views the "strong" Orion-11 results as de-risking for the additional Phase III trials. With little to pick into in the data," investor focus should shift to the commercial potential for inclisiran and the extent to which "strategic appetite exists for the asset," Fye tells investors in a research note. She continues to see a "substantial" market opportunity for inclisiran and are raised her 2030 sales forecast to $2.1B.
ARDX Ardelyx
$3.41

-0.1 (-2.85%)

04/08/19
04/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ardelyx (ARDX) initiated with an Overweight at Piper Jaffray. 2. Parker Drilling (PKD) initiated with an Outperform at Imperial Capital. 3. Frontdoor (FTDR) initiated with a Buy at Guggenheim. 4. Barnes & Noble Education (BNED) initiated with a Buy at Needham. 5. PlayAGS (AGS) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
PIPR
04/08/19
INITIATION
Target $15
PIPR
Overweight
Ardelyx initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond started Ardelyx with an Overweight rating and $15 price target. The analyst sees a "sizeable disconnect" between Wall Street's view of tenapanor's potential versus that of the nephrology community. While the drug is not fully de-risked, there is enough data to get a "strong sense" of tenapanor's ultimate clinical profile, which confers $1B-plus revenue potential, Raymond tells investors in a research note. Nephrologists appear "fully aware of this drug's potential with swift and dramatic uptake projected if approved," adds the analyst. He thinks tenapanor's launch is "poised to be one of biotech's great product launches of 2021."
CONN Conn's
$20.18

-0.31 (-1.51%)

01/22/19
STFL
01/22/19
NO CHANGE
Target $33
STFL
Buy
Conn's price target cut to $33 from $40 at Stifel
Stifel analyst John Baugh reiterated a Buy rating on Conn's and cut his price target to $33 from $40. In a research note to investors, the analyst says that while the stock is down roughly 50% since late August, he continues to believe Conn's is an attractive longer term opportunity and says the $33 price target still represents meaningful upside from current levels.
12/27/18
12/27/18
NO CHANGE

Stephens to keep GrubHub, RealPage, Vulcan Materials on 2019 Best Ideas list
Stephens said that it plans to publish a complete updated 2019 Best Ideas list on January 2, but in anticipation it shared the names that are being dropped and the three stocks that will remain on the list. The holdovers are GrubHub (GRUB), RealPage (RP) and Vulcan Materials (VMC). The stocks being removed include Boston Scientific (BSX), Brookdale Senior Living (BKD), Conn's (CONN), CoStar Group (CSGP), Curo Group (CURO), FedEx (FDX), First Financial Bancorp (FFBC), Graphic Packaging (GPK), Hub Group (HUBG), Keane Group (FRAC), KeyCorp (KEY), LKQ Corp. (LKQ), Myriad Genetics (MYGN), SVB Financial (SIVB), Triumph Bancorp (TBK), TrueCar (TRUE) and Union Bankshares (UBSH).
05/29/19
JEFF
05/29/19
NO CHANGE
Target $36
JEFF
Buy
Conn's reward outweighs risk into Q1 results, says Jefferies
Jefferies analyst Kyle Joseph likes shares of Conn's into the company's fiscal Q1 results on May 31. The combination of stable credit coupled with improving signs for the retail segment creates a favorable risk/reward, Joseph tells investors in a research note. The analyst maintains a Buy rating on the shares with a $36 price target.
12/10/18
COMP
12/10/18
UPGRADE
COMP
Buy
Conn's upgraded to Buy from Neutral at Compass Point
TUFN Tufin
$17.99

0.21 (1.18%)

06/13/19
JEFF
06/13/19
NO CHANGE
Target $28
JEFF
Buy
Tufin Q1 earnings beat should flow into Q2, says Jefferies
Jefferies analyst John DiFucci kept his Buy rating and $28 price target on Tufin after its "solid" Q1 earnings beat, saying the performance should also flow into Q2 as its license agreements accelerated slightly from the prior period. The analyst maintains his view that the company has a "vast opportunity", even though its next couple of years should be "investment years."
05/06/19
05/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PagerDuty (PD) initiated with an Overweight at Piper Jaffray, with a Neutral at BTIG, with an Outperform at William Blair, with an Overweight at JPMorgan, with a Sector Weight at KeyBanc, with an Equal Weight at Morgan Stanley and with a Sector Perform at RBC Capital. 2. Tufin (TUFN) initiated with a Buy at Jefferies, with an Overweight at Piper Jaffray, with a Market Perform at William Blair, with a Hold at Stifel, with an Outperform at Oppenheimer, with an Overweight at JPMorgan and with an Overweight at Barclay. 3. Aclaris Therapeutics (ACRS) initiated with an Outperform at SVB Leerink. 4. Jumia Technologies (JMIA) initiated with a Neutral at Citi and with a Sector Perform at RBC Capital. 5. Omeros (OMER) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
WBLR
05/06/19
INITIATION
WBLR
Market Perform
Tufin initiated with a Market Perform at William Blair
William Blair analyst Jonathan Ho initiated coverage of Tufin with a Market Perform rating saying the current valuation is fair given the company's "less predictable," slower growth rate and smaller scale relative to cybersecurity peers. However, the analyst projects a "significant opportunity" for Tufin to sustain growth and deliver operating leverage.
05/06/19
LEHM
05/06/19
INITIATION
Target $29
LEHM
Overweight
Tufin initiated with an Overweight at Barclays
Barclays analyst Saket Kalia started Tufin Software Technologies with an Overweight rating and $29 price target. The analyst thinks the network security policy management space is in early innings at less than $350M in total spending currently and runway to upwards of $10B. Further, he views Tufin is a leader in the space.
BA Boeing
$364.11

1.44 (0.40%)

08/13/19
08/13/19
DOWNGRADE

Hold
Southwest downgraded to Hold from Buy at Argus
As previously reported, Argus analyst John Staszak downgraded Southwest (LUV) to Hold, citing serious operational disruption and rising costs from Boeing's (BA) continued grounding of the 737 MAX aircraft at a time of "solid" flight demand. The analyst notes that although the stock is trading near the low end of its 5-year historical range at 11.4-times his expected 2019 earnings, he sees its valuation as reflective of the company's near term prospects for higher costs and weaker profitability.
08/06/19
RHCO
08/06/19
NO CHANGE
Target $26
RHCO
Sell
Astronics price target lowered to $26 from $35 at SunTrust
SunTrust analyst Michael Ciarmoli lowered his price target on Astronics (ATRO) to $26 and kept his Sell rating after its Q2 earnings miss and below-consensus FY19 revenue guidance. The analyst cites weak aerospace bookings as an "ominous sign" reflecting his concerns about channel destocking in addition to the company's exposure to Boeing's (BA) 737 MAX aircraft issues. Ciarmoli added that Astronics' disclosure of a satellite failure "derailing" its AeroSat antenna opportunity was an incremental negative surprise.
08/06/19
NBLE
08/06/19
UPGRADE
Target $50
NBLE
Outperform
Ducommun upgraded to Outperform from Market Perform at Noble Capital
Noble Capital analyst Christian Herbosa upgraded Ducommun (DCO) to Outperform from Market Perform after the company reported higher than expected sales and otherwise strong performance in Q2. Despite ongoing delays in the return to service of Boeing's (BA) 737 MAX, which had been a key growth driver for Ducommun in Q2, management is confident that the company can achieve 7%-9% revenue growth across commercial aerospace and military platforms for the rest of the year, noted Herbosa. He set a $50 price target on Ducommun shares.
08/22/19
BUCK
08/22/19
NO CHANGE
Target $395
BUCK
Neutral
Boeing remains a tactical buying opportunity, says Buckingham
Buckingham analyst Richard Safran reiterated his belief that Boeing remains a tactical buying opportunity and thinks the stock could go to $400-$450 driven primarily by a 9% free cash flow yield based on roughly $30/share in free cash flow in 2020. In a research note to investors, Safran says he thinks that Boeing hiring hundreds of temporary workers at its Moses Lake facility and expanding its delivery capacity is a positive sign that Boeing has confidence achieving its early fourth quarter guide for the MAX to return to service. The analyst maintains a Neutral rating and $395 price target.
ARDS Aridis Pharmaceuticals
$12.40

1.02 (8.96%)

09/10/18
09/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NMI Holdings (NMIH) initiated with an Overweight at Barclays. 2. Aridis Pharmaceuticals (ARDS) initiated with an Outperform at Northland, an Overweight at Cantor Fitzgerald, and a Buy at Laidlaw. 3. Central Garden & Pet (CENT) initiated with a Buy at BofA/Merrill. 4. GDS Holdings (GDS) initiated with an Outperform at Cowen. 5. Overstock.com (OSTK) assumed with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/18
MAXM
10/02/18
INITIATION
MAXM
Buy
Aridis Pharmaceuticals initiated with a Buy at Maxim
09/10/18
NORL
09/10/18
INITIATION
Target $40
NORL
Outperform
Aridis Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrns initiated Aridis Pharmaceuticals with an Outperform and $40 price target.
09/10/18
LDLW
09/10/18
INITIATION
Target $23
LDLW
Buy
Aridis Pharmaceuticals initiated with a Buy at Laidlaw
Laidlaw analyst Francois Brisebois started Aridis Pharmaceuticals with a Buy rating and $23 price target. The analyst believes the company's "fairly late stage differentiated clinical pipeline" could more efficiently fulfill unmet medical and financial needs.
PUMP ProPetro Holding
$10.65

-0.01 (-0.09%)

09/03/19
PIPR
09/03/19
DOWNGRADE
PIPR
Neutral
ProPetro Holding downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst John Daniel downgraded ProPetro Holding to Neutral from Overweight.
08/13/19
STFL
08/13/19
NO CHANGE
Target $21
STFL
Buy
ProPetro risk/reward looks 'very compelling' after 30% pullback, says Stifel
Stifel analyst Stephen Gengaro noted that shares of ProPetro Holding are down 29.6% over the past two days following its "lackluster" quarterly results and 10-Q delay due to an ongoing review by its audit committee. While the situation shows a lack of necessary controls, he does not believe there were "nefarious intentions," said Gengaro, who added that the amount of detail in the press release gave him the impression that the review process is close to completion and the 10-Q will be filed within 30 days. The analyst, who also thinks that Dale Redman will remain as CEO, sees the risk/reward as "very compelling" at current levels. He cut his price target on ProPetro shares to $21 from $31 but maintains a Buy rating on the stock.
08/12/19
WELS
08/12/19
NO CHANGE
Target $22
WELS
Outperform
ProPetro Holding price target lowered to $22 from $27 at Wells Fargo
Wells Fargo analyst Christopher Voie lowered his price target for ProPetro Holding to $22 from $27 following the company's disclosure of an audit committee's review of its disclosures of agreements with AF Global, its related party transaction disclosures, and its expense reimbursement practices that found $370K of incorrectly reimbursed expenses by ProPetro's CEO and CFO drove significant underperformance in the shares. The analyst continues to model ProPetro assuming the management team remains intact, but acknowledges significant risk to his forecasts depending on how the review unfolds. He reiterates an Outperform rating on the shares.
09/03/19
PIPR
09/03/19
DOWNGRADE
Target $17
PIPR
Neutral
Piper downgrades ProPetro on uncertainty following general counsel exit
Piper Jaffray analyst John Daniel downgraded ProPetro Holding to Neutral from Overweight and cut his price target for the shares to $17 from $32.50. The resignation of its general counsel adds uncertainty to the company's audit review, Daniel tells investors in a research note. The situation seems "more complex" than originally perceived, adds the analyst.

TODAY'S FREE FLY STORIES

STX

Seagate

$56.92

0.88 (1.57%)

13:35
09/18/19
09/18
13:35
09/18/19
13:35
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NLSN

Nielsen

$22.45

-0.13 (-0.58%)

13:34
09/18/19
09/18
13:34
09/18/19
13:34
Periodicals
Nielsen acquires minority stake in brand-safety company Open Slate, WSJ reports »

Nielsen Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$52.93

-0.57 (-1.07%)

13:30
09/18/19
09/18
13:30
09/18/19
13:30
Periodicals
Blackstone near $2.9B deal to buy Great Wolf Resorts, Bloomberg says »

Privately held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 26

    Sep

RUBI

Rubicon Project

$9.36

-0.05 (-0.53%)

, TLRA

Telaria

$8.03

-0.195 (-2.37%)

13:26
09/18/19
09/18
13:26
09/18/19
13:26
Recommendations
Rubicon Project, Telaria, Trade Desk analyst commentary  »

Google auction shift…

RUBI

Rubicon Project

$9.36

-0.05 (-0.53%)

TLRA

Telaria

$8.03

-0.195 (-2.37%)

TTD

Trade Desk

$209.29

-3.72 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 30

    Sep

  • 07

    Nov

  • 12

    Nov

FDX

FedEx

$149.76

-23.77 (-13.70%)

13:25
09/18/19
09/18
13:25
09/18/19
13:25
Downgrade
FedEx rating change  »

FedEx downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

13:25
09/18/19
09/18
13:25
09/18/19
13:25
Conference/Events
The SEC to hold a meeting to hear oral arguments »

The Commission will hear…

SOLO

ElectraMeccanica

$2.40

0.04 (1.69%)

13:24
09/18/19
09/18
13:24
09/18/19
13:24
Initiation
ElectraMeccanica initiated  »

ElectraMeccanica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UN

Unilever; also tag UL

$60.45

0.01 (0.02%)

, PG

Procter & Gamble

$121.47

0.32 (0.26%)

13:23
09/18/19
09/18
13:23
09/18/19
13:23
Recommendations
Unilever; also tag UL, Procter & Gamble, Unilever; also tag UN, Reckitt Benckiser, Henkel, L'Oreal analyst commentary  »

EU Household &…

UN

Unilever; also tag UL

$60.45

0.01 (0.02%)

PG

Procter & Gamble

$121.47

0.32 (0.26%)

UL

Unilever; also tag UN

$61.51

0.05 (0.08%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

HENKY

Henkel

$0.00

(0.00%)

LRLCY

L'Oreal

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 08

    Oct

  • 18

    Oct

  • 12

    Nov

NRC

National Research Corporation

$63.59

1.59 (2.56%)

13:23
09/18/19
09/18
13:23
09/18/19
13:23
Hot Stocks
National Research Corporation director Donald Berwick sold over $433K in shares »

National Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$188.14

0.01 (0.01%)

, TWTR

Twitter

$42.66

-0.59 (-1.36%)

13:22
09/18/19
09/18
13:22
09/18/19
13:22
On The Fly
#SocialStocks: Facebook clarifies oversight structure, Snap in talks to add news »

Welcome to…

FB

Facebook

$188.14

0.01 (0.01%)

TWTR

Twitter

$42.66

-0.59 (-1.36%)

SNAP

Snap

$16.77

-0.1 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/18/19
09/18
13:17
09/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/18/19
09/18
13:16
09/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$259.19

-0.47 (-0.18%)

13:15
09/18/19
09/18
13:15
09/18/19
13:15
Conference/Events
Tyler Technologies management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Sep

  • 26

    Sep

BRKR

Bruker

$43.21

0.34 (0.79%)

13:14
09/18/19
09/18
13:14
09/18/19
13:14
Conference/Events
Bruker management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

RST

Rosetta Stone

$18.99

-0.22 (-1.15%)

13:13
09/18/19
09/18
13:13
09/18/19
13:13
Conference/Events
Rosetta Stone management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:07
09/18/19
09/18
13:07
09/18/19
13:07
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Cryoport CEO says Seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

, GILD

Gilead

$65.78

-0.39 (-0.59%)

13:05
09/18/19
09/18
13:05
09/18/19
13:05
On The Fly
Meet Cryoport: A Fly exclusive interview with CEO Jerry Shelton »

In an exclusive interview…

CYRX

Cryoport

$17.92

0.17 (0.96%)

GILD

Gilead

$65.78

-0.39 (-0.59%)

NVS

Novartis

$86.46

-0.11 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Shelton sees Cryoport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Cryoport, Vineti…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

, GILD

Gilead

$65.80

-0.37 (-0.56%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport, Gilead, Novartis »

Gilead, Novartis…

CYRX

Cryoport

$17.92

0.17 (0.96%)

GILD

Gilead

$65.80

-0.37 (-0.56%)

NVS

Novartis

$86.46

-0.11 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

AEGN

Aegion

$20.77

-0.46 (-2.17%)

13:03
09/18/19
09/18
13:03
09/18/19
13:03
Hot Stocks
Aegion unit awarded $9.3M contract from MWRD in Denver »

Aegion announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

BYND

Beyond Meat

$157.51

-2.86 (-1.78%)

, QSR

Restaurant Brands

$73.77

-0.08 (-0.11%)

13:01
09/18/19
09/18
13:01
09/18/19
13:01
Periodicals
Tim Hortons to pull back on Beyond Meat offerings, Journal de Montreal says »

A translation of a French…

BYND

Beyond Meat

$157.51

-2.86 (-1.78%)

QSR

Restaurant Brands

$73.77

-0.08 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BX

Blackstone

$52.97

-0.53 (-0.99%)

13:01
09/18/19
09/18
13:01
09/18/19
13:01
Periodicals
Breaking Periodicals news story on Blackstone »

Blackstone near $2.9B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 26

    Sep

RYAAY

Ryanair

$61.95

-0.14 (-0.23%)

12:53
09/18/19
09/18
12:53
09/18/19
12:53
Initiation
Ryanair initiated  »

Ryanair initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$300.17

-0.77 (-0.26%)

12:47
09/18/19
09/18
12:47
09/18/19
12:47
Hot Stocks
Gundlach sees 'increasing probability' of recession before 2020 election »

Jeffrey Gundlach of…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$300.17

-0.77 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.